Company intelligence / Profile preview

POCTech

Huzhou, Zhejiang, China

Ownership: Private
Development stage: Commercial

Overview

The CT‑100 subcutaneous continuous glucose monitoring system completed a clinical trial in 2015 with 80 patients. It demonstrated a mean absolute relative difference (MARD) of ~9% compared to finger sticks and venous blood glucose. Clarke’s error grid analysis showed >88% of readings in the clinically accurate A zone. The product has obtained CE Mark certification and is commercially available or ready for distribution in Europe.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Device (Continuous Glucose Monitoring system)Biosensor-based device
Industry: Physiological Monitoring

Partnerships

Ascensia Diabetes Care (exclusive distributor/co-development partner for global markets)

Beyond the preview

Go deeper on POCTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on POCTech.

Explore the full profile